Biotech Bullish Stocks: Regulus Therapeutics Inc (NASDAQ:RGLS), Insys Therapeutics (NASDAQ:INSY), Repligen Corporation (NASDAQ:RGEN), Sarepta Therapeutics (NASDAQ:SRPT)

Gilead Sciences GILD NASDAQ:GILD

Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) were the target of a significant decrease in short interest in January. As of March 14th, there was short interest totaling 1,460,571 shares, a decrease of 20.3% from the February 28th total of 1,832,140 shares, Analyst Ratings Newsreports. Regulus Therapeutics Inc (NASDAQ:RGLS) stock performance was 5.09% in last session and finished the day at $7.64. Traded volume was 161,836.00million shares in the last session and the average volume of the stock remained 230.17K shares. Regulus Therapeutics Inc (NASDAQ:RGLS) insider ownership is 0.20%.

Insys Therapeutics, Inc. (NASDAQ:INSY), a specialty pharmaceutical company with focus on supportive care products for cancer patients, will visit the NASDAQ MarketSite in Times Square. In honor of the occasion, Michael Babich, Chief Executive Officer will ring the Opening Bell. Insys Therapeutics Inc (NASDAQ:INSY) rose 5.40 percent to $37.06 Monday on volume of 511,720.00million shares. The intra-day range of the stock was $34.88 to $37.69. Insys Therapeutics Inc (NASDAQ:INSY) has a market capitalization of $1.24billion.

On March 26, 2014, Repligen Corporation (NASDAQ:RGEN) announced the commercial launch of its OPUS® 45 cm diameter columns (OPUS 45) with the largest capacity currently available on the market. The Company noted that OPUS 45 aims to process large single-use bioreactor harvests. Repligen Corporation (NASDAQ:RGEN)’s stock on Apr 07, 2014 reported a increase of 6.33% to the closing price of $14.10. Its fifty two weeks range is $7.37 -$17.26. The total market capitalization recorded $450.29million. The overall volume in the last trading session was 1.12million shares. In its share capital, RGEN has 31.94million outstanding shares.

Needham & Company analyst Chad Messer confirmed to that Sarepta Therapeutic Inc (NASDAQ: SRPT) did in fact cancel from the Needham Healthcare conference scheduled tomorrow. A Sarepta Therapeutics Inc (NASDAQ: SRPT) spokesperson confirmed the cancellation saying, “unfortunately we had to cancel due to other obligations that prevent us from participating.” On Monday, shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) advanced 7.29% to close the day at $24.73. Company return on investment (ROI) is -36.30% and its monthly performance is recorded as -10.37%. Sarepta Therapeutics Inc (NASDAQ:SRPT) quarterly revenue growth is 31.75%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone